CanSino Biologics' (06185.HK) recombinant polio vaccine has been approved for clinical trials in China.

Zhixin Financial News App reported that CanSino Biologics (06185.HK) announced that the recombinant trivalent rabies vaccine (Sf-RVN cells) developed by the company has been approved by the China National Medical Products Administration for conducting related clinical trials.